Vertex Pharmaceuticals Incorporated (VRTX) News
Vertex Pharmaceuticals Incorporated (VRTX)
Today's Latest Price: $207.01 USD
Updated Oct 29 4:00pm
Add VRTX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
Filter VRTX News Items
VRTX News Results
| Event/Time | Symbol | Company | News Detail | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest VRTX News From Around the Web
Below are the latest news stories about Vertex Pharmaceuticals Inc that investors may wish to consider to help them evaluate VRTX as an investment opportunity.
Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR ModulatorsBOSTON--(BUSINESS WIRE)-- #ECFS2020--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 43rd European Cystic Fibrosis Digital Conference (ECFS) held September 24-25, 2020 and the 2020 North American Cystic Fibrosis Virtual Conference (NACFC) taking place October 7-23, 2020. An oral presentation at the ECFS Digital Conference will highlight, for the first time, interim results from the TRIKAFTA |
Crispr: The Frontier Of Gene EditingThe greatest investment reward comes to those who by good luck or good sense find the occasional company that over the years can grow far more than the industry as a whole. - Phillip Fisher (Warren Buffett's mentor asides from Ben Graham) As you can see, biotech is a lucrative... |
The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPOHere's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) ... |
Thinking about buying stock in Delta Air Lines, Scientific Games, GameStop, Vertex Pharmaceuticals, or Fortress Biotech?NEW YORK, Sept. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DAL, SGMS, GME, VRTX, and FBIO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link…. |
Vertex Announces European Medicines Agency Type II Variation Marketing Authorization Application Validation for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination with ivacaftor in People with One Copy of the F508del MutationLONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the European Medicines Agency (EMA) has validated a Type II Variation Marketing Authorization Application (MAA) for the expanded indication of KAFTRIO®* (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor to treat CF in patients ages 12 years and older with at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. If approved, eligible |
Vertex Pharmaceuticals reports 7.1% stake in Kymera TherapeuticsVertex Pharmaceuticals (VRTX) acquires ~3.15M shares of Kymera Therapeutics (KYMR), representing 7.1% of its total shares outstanding.Shares were acquired pursuant to Vertex’s collaboration with Kymera and in a private placement that was closed concurrently with the closing of Kymera’s IPO on August 25, 2020.Vertex had paid an initial consideration of... |
Vertex Pharmaceuticals Incorporated 2020 Q2 - Results - Earnings Call PresentationThe following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2020 Q2 earnings call.... |
Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q2 2020 Results - Earnings Call TranscriptVertex Pharmaceuticals, Inc. (VRTX) Q2 2020 Earnings Conference Call July 30, 2020, 5:30 PM ET Company Participants Michael Partridge - SVP, IR Reshma Kewalramani - CEO, President & Director Stuart Arbuckle - EVP & Chief Commercial Officer Charles Wagner - EVP & CFO Conference Call Participants Cory Kasimov - JPMorgan... |
Vertex (VRTX) Q2 Earnings & Sales Beat, Revenue Guidance UpVertex (VRTX) raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading. |
How Vertex Pharmaceuticals Wowed With Its Q2 ResultsVertex Pharmaceuticals (NASDAQ: VRTX) has been on a roll so far in 2020. The company announced its second-quarter results after the market closed on Thursday. It looks like Vertex's good times will keep rolling. |
